- CIIX
anticipates launch of hemp-infused wrinkle cream in China
- Through
subsidiary CBD Biotech, CIIX will focus hemp and CBD products on the
blooming Chinese market
- The
company noted impressive sales, revenue growth for Q1 2020, greatly due to
success of CBD Biotech
ChineseInvestors.com
Inc. (OTCQB: CIIX) CEO Warren Wang noted the enormous potential for
cosmetics infused with industrial hemp in a RedChip Money Report interview.
This sentiment was echoed in his letter to shareholders, where he noted that
CBD-infused cosmetics will the company and its subsidiary, CBD Biotech, to a
Chinese market of 1.4 billion people. CIIX plans to launch industrial
hemp-infused wrinkle cream cosmetics to this market in the near future (http://ibn.fm/4G7xU).
In the interview, Wang outlined the company’s historic
presence in China’s’s burgeoning CBD-industry. As the first company to enter
the Chinese CBD products market, the move represents tremendous opportunity for
CIIX’s CBD division, he said. Additionally, the company has been marketing its
CBD products to Chinese-speaking American consumers since it entered the
industry in 2017. Wang referenced the incredible market potential of the more
than 3.5 million Chinese consumers in the United States, to which CIIX already
markets gummies, CBD oil, and CBD-infused cosmetics (http://ibn.fm/EQcsr).
Looking forward, Wang described the company’s intent to
diversify its revenue streams in FY2020, planning to focus on its core investor
relations business as well as continuing to expand and market its industrial
hemp-infused/CBD products in China and the United States. This strategy shows
potential for greater revenues and profits, as “the buying power from the
Chinese consumer will be huge,” he said.
“While cannabis use in China is illegal, cannabis-based oils
including industrial hemp extract may be added to cosmetics, thus opening a
potential market of nearly 1.4 billion people for the company,” Wang noted. “As
we analyze the legality/trends in other Asian countries, we have an advantage
with ‘feet on the ground’ in that part of the world.”
CIIX will also focus in 2020 on its core business of
investor relations. It already owns a minority interest in a U.S.-based
investment bank, Donald Capital, LLC and is in the process of establishing a
“working cooperation” with a private equity firm in China. Wang said, “Both of
these relationships are projected to be a source of recurring revenue for years
to come.”
This continued emphasis on its CBD arm has led CIIX to
impressive revenue reporting. CIIX reported in its 8K filing to the SEC sharply
higher revenues for Q1 2020, the three months ended August 31, 2019. Sales
jumped to $1,956,960, 174.7% higher than the $712,360 for the same quarter the
prior year. Hemp and CBD product revenues drove that increase with a
contribution of $948,751 for the 2020 quarter, a 569.2% rise from the $141,764
in Q1 2019 (http://ibn.fm/nArjp).
Additionally, CIIX’s core investor relations business
generated $821,361 in Q1 2020, a 200% improvement over the $271,248 the same
period the prior year. CIIX has refocused and grown its core business (http://ibn.fm/cltnt).
With an eye toward profitability, CIIX is streamlining its
operations and maximizing current resources across the board. As it refocuses
on its core investor relations business and diversifies and grows its
industrial hemp/infused products in China and the U.S., Wang is optimistic.
Wang said, “Although we still have work to do in this regard, with these
objectives in mind, with a dedicated and experienced management team, and most
importantly, the continued support of our loyal shareholders, we look forward
to a healthy FY2020.”
CIIX offers its audience of Chinese-speaking investors real
time market commentary, analysis and educational-related services in Chinese
character language sets. When asked why investors should put their trust in
CIIX, Wang said, “We have been around for 20 years. We put our roots into the
United States of America, so I believe people can trust us. We are right here,
right now, and local.” CIIX offers investors an inexpensive stock option poised
on the brink of tremendous market opportunity in China’s growing CBD-infused
cosmetic industry.
For more information, visit the company’s website at www.ChineseInvestors.com
NOTE TO INVESTORS: The latest news and updates
relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
